“The third quarter was marked by important milestones outlining the next steps for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “The FDA gave us the green light to initiate confirmatory Phase 3 studies for early AD, and our team has been working hard to begin them in the coming year. We also strengthened our intellectual property portfolio by filing unique patents protecting new combinations of buntanetap with other medications for improving cognition.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio appoints Peterson as Senior Clinical Scientist
- Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Annovis Bio upgraded to Buy at Maxim following buntanetap update
- Annovis Bio upgraded to Buy from Hold at Maxim
- Annovis Bio says FDA clears company to launch Phase 3 Alzheimer’s studies